ABSTRACT
Context Peritoneal endometriosis (PE) remains challenging to diagnose, as it cannot be detected using standard imaging modalities and no clinically validated biomarkers are available.
Objective To identify novel blood-based biomarkers for PE using whole blood transcriptomics combined with machine learning approaches.
Design, Setting, and Patients This observational study enrolled 48 women undergoing laparoscopic surgery for endometriosis-related symptoms at tertiary referral centres in Slovenia and Austria. Patients were classified as having PE (n=20), peritoneal and ovarian endometriosis (PE and OE, n=8), or no endometriosis (controls, n=20). Patients were further stratified by menstrual phase (proliferative or secretory). Whole blood samples were collected preoperatively.
Methods Whole-blood RNA sequencing was performed, and differentially expressed genes (DGEs) and transcripts (DTEs) were identified. Sequencing data were processed using a machine learning pipeline to select key features and develop support vector machine (SVM) classifiers for predicting endometriosis status.
Results In the proliferative group, no DGEs and only two DTEs distinguished PE from controls. In contrast, in the secretory group, 1,035 DGEs and 922 DTEs were identified, with no overlap between menstrual phases. Enrichment analysis of secretory phase DGEs indicated their involvement in angiogenesis and immune-related pathways. Feature selection identified six transcripts that achieved the best SVM classification performance in distinguishing cases from controls across both menstrual phases (AUC = 0.92, sensitivity = 75%, specificity = 100%).
Conclusion This study provides first evidence that integrating whole-blood transcriptomics with machine learning can identify potential blood-based biomarkers for PE and highlights the influence of menstrual cycle phase. These findings require validation in larger, independent cohort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grants J3-1755 and P3-0449 to T.L.R. and Z3-4522 to M.P.N. from the Slovenian Research and Innovation Agency).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the National Medical Ethics Committee of the Republic of Slovenia (approval no. 120-5412019-5), and the Republic of Austria (approval no. 545/2010).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
